HUENENBERG, Switzerland--(BUSINESS WIRE)--The Alcon Independent Director Committee (the “IDC”) responded today to Novartis’ continued assertions that they can circumvent the protections afforded to Alcon’s minority shareholders and reiterated its commitment to defend the minority shareholders’ rights.
